FrancophonIA/ELRC3.0 huggingface dataset:
English: In its letter notifying the Agency of the withdrawal of the application, the company stated that it would not be possible for them to reply to the Agency's concerns within the agreed timeframe.
Estonian: Ettevõtte kirjas, milles ta teatab Euroopa Ravimiametile oma taotluse tagasivõtmisest, märgib ettevõte, et tal ei ole ameti tõstatatud probleemidele võimalik ettenähtud tähtajaks vastata.
English: The beneficial effects seen were considered modest, particularly in patients who also took statins, and were not considered to outweigh the increased risks of serious infections in patients treated with the medicine.
Estonian: Täheldatud kasulikke toimeid peeti tagasihoidlikuks, eriti samal ajal ka statiine kasutavatel patsientidel, ning inimravimite komitee oli arvamusel, et ravimi kasulikkus ei ole suurem kui sellega kaasnev raskete infektsioonide riski suurenemine ravimit kasutavatel patsientidel.
English: In particular, the CHMP was of the opinion that the data provided by the company was not robust enough to clearly demonstrate that canakinumab Novartis is effective in all patients who have had a heart attack.
Estonian: Seetõttu oli inimravimite komitee arvamusel, et ettevõtte esitatud andmed ei ole piisavalt kindlad, et selgelt tõestada Canakinumab Novartise efektiivsust kõigil patsientidel, kellel on olnud südamelihase infarkt.
English: The CHMP also questioned the appropriateness of the measure chosen by the company to select patients and to monitor the effectiveness of canakinumab Novartis.
Estonian: Inimravimite komitee väljendas ettevaatlikkust ka meetodi, kuidas ettevõte valis patsiente ja jälgis Canakinumab Novartise efektiivsust.
English: Canakinumab Novartis was expected to be used to prevent serious events such as stroke, heart attack or death in patients who have already had a heart attack.
Estonian: Canakinumab Novartist kavatseti kasutada raskete sündmuste, näiteks insuldi, südamelihase infarkti või surma ennetamiseks patsientidel, kellel on olnud südamelihase infarkt.
English: The company informed the CHMP that, while an extension to the above-mentioned study will stop, other studies investigating canakinumab for the treatment of other conditions will continue as planned.
Estonian: Ettevõte teatas inimravimite komiteele, et kuigi eespool nimetatud uuringu jätku-uuring lõpeb, jätkuvad uuringud, mis käsitlevad kanakinumaabi kasutamist muude seisundite ravis.
English: The active substance in canakinumab Novartis, canakinumab, is a monoclonal antibody (a type of protein) which has been designed to recognise and attach to interleukin 1 (IL-1) beta.
Estonian: Canakinumab Novartise toimeaine kanakinumaab on monoklonaalne antikeha (teatud valk), mis tunneb ära valgu IL-1β (beeta-interleukiin 1) ja seondub sellega.
English: What is canakinumab Novartis?
Estonian: Mis on Canakinumab Novartis?
English: Canakinumab Novartis is a medicine that contains the active substance canakinumab.
Estonian: Canakinumab Novartis on ravim, mis sisaldab toimeainena kanakinumaabi.
English: Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal, the CHMP had remaining concerns and was of the provisional opinion that canakinumab Novartis could not have been approved for the prevention of serious heart problems in patients who have already had a heart attack.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi Canakinumab Novartis kasutamist raskete sündmuste ennetamiseks patsientidel, kellel on olnud südamelihase infarkt, ei ole võimalik heaks kiita.
English: It was to be available as a solution for injection under the skin in pre-filled pens and pre-filled syringes.
Estonian: Seda kavatseti turustada subkutaanse (nahaaluse) süstelahusena eeltäidetud pensüstaldes ja eeltäidetud süstaldes.
English: By attaching to IL-1 beta, canakinumab blocks its activity and reduces inflammation.
Estonian: IL-1β-ga seondudes blokeerib kanakinumaab selle toime ja vähendab põletikku.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the benefits of canakinumab Novartis did not outweigh its risks.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ravimi Canakinumab Novartis kasulikkus ei ole suurem kui sellega kaasnevad riskid.
English: How does canakinumab Novartis work?
Estonian: Kuidas Canakinumab Novartis toimib?
English: On 4 December 2018, Novartis Europharm Ltd. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for canakinumab Novartis, for the prevention of serious events such as stroke, heart attack or death in patients who have had a heart attack.
Estonian: Novartis Europharm Ltd. teatas 4. detsembril 2018 inimravimite komiteele oma soovist võtta tagasi ravimi Canakinumab Novartis müügiloa taotlus.
English: commonly used to prevent heart problems, such as statins.
Estonian: Patsiendid kasutasid ka muid ravimeid, mida sageli kasutatakse südameprobleemide ennetamiseks, näiteks statiine.
English: EMA/865778/2018
Estonian: Müügiloa taotluse tagasivõtmise teave: Canakinumab Novartis (kanakinumaab) EMA/865778/2018
English: What was canakinumab Novartis expected to be used for?
Estonian: Milleks kavatseti Canakinumab Novartist kasutada?
English: The European Commission granted a marketing authorisation valid throughout the European Union, for Convenia on 19 June 2006.
Estonian: Euroopa Komisjon väljastas Convenia müügiloa, mis on kehtiv kogu Euroopa Liidu territooriumil, 19. juunil 2006.
English: cefovecin
Estonian: Tsefovetsiini
English: Depending on the infection concerned, the injection can be repeated if necessary (up to three times).
Estonian: Olenevalt nakkusest võib süsti vajadusel korrata (kuni kolm korda).
English: One injection lasts for up to 14 days.
Estonian: Ühe süsti toime püsib kuni 14 päeva.
English: Other information about Convenia:
Estonian: Muu teave Convenia kohta
English: Treated animals should not be used for breeding for 12 weeks after the last injection of Convenia.
Estonian: Ravitud loomi ei tohi kasutada aretamiseks 12 nädala jooksul pärast viimast Convenia süsti.
English: No side-effects have been reported with Convenia to date.
Estonian: Convenia kohta ei ole seni kõrvalnähtudest teatatud.
English: Convenia has the benefit of a long duration of activity.
Estonian: Convenia eeliseks on selle pikaajaline toime.
English: Swelling of the face, lips or eyes, or any difficulty breathing are more serious symptoms and require urgent medical attention.
Estonian: Näo, huulte või silmade turse või hingamisraskused on tõsisemad sümptomid ja vajavad kiiret arstiabi.
English: Like other antibiotics, cefovecin is not effective against all types of bacteria.
Estonian: Nagu teisedki antibiootikumid, ei ole tsefovetsiin efektiivne igat liiki bakterite suhtes.
English: The studies measured the rate at which the infections were cured.
Estonian: Uuringutes mõõdeti nakkuste hävimise määra.
English: What is the risk associated with Convenia?
Estonian: Millised on Conveniaga kaasnevad riskid?
English: Convenia should therefore not be handled by anyone who is hypersensitive (allergic) to such antibiotics, or by anyone who has been advised not to work with them.
Estonian: Seepärast ei tohi Conveniat käsitseda isikud, kellel esineb ülitundlikkus (allergia) nende antibiootikumide suhtes või kellel ei ole soovitatud nendega töötada.
English: It would be dangerous to use Convenia in other animals such as guinea pigs and rabbits (it is not licensed for use in these species).
Estonian: Conveniat on ohtlik kasutada teistel loomadel, näiteks merisigadel või küülikutel (seda ei ole lubatud neil loomaliikidel kasutada).
English: Cephalosporin and penicillin antibiotics can cause allergies in humans, and sometimes these allergies can be very serious.
Estonian: Tsefalosporiinide ja penitsilliinide hulka kuuluvad antibiootikumid võivad põhjustada inimestel allergiat, mis võib olla mõnikord väga raske.
English: However, it should not be used in dogs or cats which have shown an allergy to any cephalosporin or penicillin-type antibiotics.
Estonian: Kuid seda ei tohiks kasutada koertel ja kassidel, kellel on esinenud allergiat ükskõik millise tsefalosporiini või penitsilliini tüüpi antibiootikumi suhtes.
English: As no studies have been made in breeding animals with Convenia and it has an exceptionally long duration in the body, Convenia should not be used in pregnant or lactating dogs or cats.
Estonian: Kuna Conveniaga ravitud loomade aretamist ei ole uuritud ja see püsib kehas erakordselt kaua, ei tohi Conveniat kasutada tiinetel või imetavatel koertel või kassidel.
English: What are the precautions for the person who gives the medicine or comes into contact with the animal?
Estonian: Milliseid ettevaatusabinõusid peab loomale ravimit andev või loomaga kokku puutuv isik rakendama?
English: Convenia should be handled with care and all the recommended precautions be taken to avoid exposure to the product.
Estonian: Convenia käsitsemisel tuleb olla ettevaatlik ja ravimiga kokkupuutumisel tuleb rakendada kõiki soovitatud ettevaatusabinõusid.
English: Why has Convenia been approved?
Estonian: Miks Convenia heaks kiideti?
English: In all studies, Convenia was as effective in curing the infection as the comparator antibiotic.
Estonian: Convenia oli kõikides uuringutes nakkuste ravimisel sama efektiivne kui võrreldav antibiootikum.
English: If any symptoms occur after accidental exposure to Convenia, for example a skin rash, then the advice of a doctor should be sought immediately.
Estonian: Sümptomite, näiteks nahalööbe tekkimisel pärast juhuslikku kokkupuutumist Conveniaga tuleb pöörduda kohe arsti poole.
English: There are two vials in each pack of Convenia, one vial containing a powder, and one vial containing the diluent.
Estonian: Convenia pakendis on kaks viaali, millest üks sisaldab pulbrit ja teine lahustit.
English: Convenia should also not be used in dogs or cats of less than 8 weeks old, or in dogs or cats with severe kidney problems (renal dysfunction).
Estonian: Conveniat ei tohiks kasutada ka vähem kui 8 nädala vanustel või raskete neeruprobleemidega (neerutalitlushäirega) koertel või kassidel.
English: All these cephalosporin antibiotics, including cefovecin, kill bacteria by disrupting the building of the bacterial cell walls, so the bacteria die and the infection is cured.
Estonian: Kõik tsefalosporiinide hulka kuuluvad antibiootikumid, kaasa arvatud tsefovetsiin, hävitavad baktereid bakterirakkude seinte lagundamise teel, mille tulemusena bakter hävib ja nakkus kaob.
English: What is Convenia?
Estonian: Mis on Convenia?
English: The powder is dissolved in the diluent before use to make up a solution for injection.
Estonian: Süstelahuse valmistamiseks lahustatakse pulber enne kasutamist lahustis.
English: It is generally given as a single injection, and the effect of the injection lasts for up to 14 days.
Estonian: Seda manustatakse tavaliselt ühekordse süstina, mille toime püsib kuni 14 päeva.
English: Cefovecin differs from other similar cephalosporin antibiotics as it stays in the dog's or cat's body for a very long time after it has been injected.
Estonian: Tsefovetsiin erineb teistest samalaadsetest tsefalosporiinide hulka kuuluvatest antibiootikumidest selle poolest, et see püsib pärast süstimist koera või kassi kehas väga kaua.
English: Anyone allergic to penicillins or cephalosporins should also avoid contact with litter used by dogs or cats treated with Convenia.
Estonian: Penitsilliinide või tsefalosporiinide suhtes allergilised isikud peavad vältima ka kokkupuudet Conveniaga ravitud koerte või kasside poolt kasutatud liivaga.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Convenia exceed the risks for the treatment of dogs and cats with certain specified skin, soft tissue and urinary tract infections and recommended that Convenia should be given a marketing authorisation.
Estonian: Veterinaarravimite komitee jõudis järeldusele, et Convenia kasulikkus teatavate naha, pehmete kudede ja kuseteede infektsioonidega koerte ja kasside ravis on suurem kui sellega kaasnevad riskid, ning soovitas anda Conveniale müügiloa.
English: Convenia is used to treat infections caused by certain specific bacteria (see the SPC for further details).
Estonian: Conveniat kasutatakse teatavate bakterite põhjustatud nakkuste raviks (vt lähemalt ravimi omaduste kokkuvõttest).
English: Data from laboratory studies with different bacteria showed that cefovecin was effective against the bacteria specified in the product information (SPC and package leaflet).
Estonian: Laboratoorsetes uuringutes erinevate bakteritega näidati tsefovetsiini efektiivsust ravimiteabes (ravimi omaduste kokkuvõte ja pakendi infoleht) märgitud bakterite suhtes.
English: The active substance in Convenia is cefovecin which belongs to a class of antibiotics called third generation cephalosporins.
Estonian: Convenia toimeaine tsefovetsiin on antibiootikum, mis kuulub kolmanda põlvkonna tsefalosporiinide hulka.
English: What benefit has Convenia shown during the studies?
Estonian: Milles seisneb uuringute põhjal Convenia kasulikkus?
English: Convenia is used in cats to treat skin and soft tissue infections, such as wounds and abscesses.
Estonian: Kassidel kasutatakse Conveniat naha ja pehmete kudede nakkuste, näiteks haavade ja mädanike raviks.
English: It is also used in dogs to treat urinary tract infections caused by certain specific bacteria.
Estonian: Samuti kasutatakse seda koertel ka teatavate bakterite põhjustatud kuseteedenakkuste raviks.
English: How has Convenia been studied?
Estonian: Kuidas Conveniat uuriti?
English: Convenia contains cefovecin, an antibiotic which is given by injection (under the skin).
Estonian: Convenia sisaldab tsefovetsiini, mis on (naha alla) süstitav antibiootikum.
English: Convenia has also been studied in cats with skin and soft tissue infections (where it was compared to another antibiotic containing amoxicillin and clavulanic acid), and in a small study in cats with urinary tract infections, where it was compared with cefalexin.
Estonian: Conveniat on uuritud ka naha ja pehmete kudede nakkustega kasside ravis (võrreldes teise antibiootikumiga, mis sisaldab amoksitsilliini ja klavulaanhapet) ja väikeses uuringus kuseteede nakkusega kasside ravis võrreldes tsefaleksiiniga.
English: It is also used in cats to treat urinary tract infections caused by certain specific bacteria.
Estonian: Samuti kasutatakse seda kassidel ka teatavate bakterite põhjustatud kuseteedenakkuste raviks.
English: How does Convenia work?
Estonian: Kuidas Convenia toimib?
English: Convenia has been studied in dogs with skin and soft tissue infections (where it was compared to another antibiotic containing amoxicillin and clavulanic acid) and in dogs with urinary tract infections (where it was compared to another cephalosporin antibiotic, cefalexin).
Estonian: Conveniat on uuritud naha ja pehmete kudede nakkustega koerte ravis (võrreldes teise antibiootikumiga, mis sisaldab amoksitsilliini ja klavulaanhapet) ja kuseteede nakkustega koerte ravis (võrreldes teise tsefalosporiinide hulka kuuluva antibiootikumi tsefaleksiiniga).
English: What is Convenia used for?
Estonian: Milleks Conveniat kasutatakse?
English: Convenia is used in dogs to treat skin and soft tissue infections; these are infections on the skin and in the layers just below the skin, such as wounds, abscesses and pyoderma (a skin infection with a rash and pustules).
Estonian: Conveniat kasutatakse koertel naha ja pehmete kudede nakkuste raviks: nahal ja vahetult nahaalustes kihtides esinevate infektsioonide, näiteks haavade, mädanike ja mädanahksuse (lööbe ja pustulitega nahainfektsioon) raviks.
English: 1 dose (0.5 ml) contains:
Estonian: 1 doos (0,5 ml) sisaldab:
English: Tetanus toxoid*
Estonian: Teetanuse toksoid*
English: Inactivated Bordetella pertussis strain** Hepatitis B virus surface antigen recombinant** (S protein)***
Estonian: Inaktiveeritud Bordetella pertussis tüvi** Hepatiidi B-viiruse rekombinantne pinnaantigeen** (S proteiin)***
English: 2.5 micrograms conjugated to tetanus toxoid as a carrier adsorbed on aluminium hydroxide hydrated Total: 0.26 milligrams Al3+ ** adsorbed on aluminium phosphate Total: 0.40 milligrams Al *** produced in Saccharomyces cerevisiae cells by recombinant DNA technology
Estonian: Kokku: 0,26 milligrammi Al ** adsorbeeritud alumiiniumfosfaadil Kokku: 0,40 milligrammi Al *** Valmistatud Saccharomyces cerevisiae rakkudes rekombinantse DNA tehnoloogiaga.
English: Diphtheria toxoid*
Estonian: Difteeria toksoid*
English: Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 2
Estonian: Haemophilus influenzae b-tüüpi polüsahhariid (polüribosüülribitoolfosfaat)
English: Content
Estonian: Nimetus
English: Invented nam Strength Pharmaceutical
Estonian: Tugevus Ravimvorm Manustamisviis Pakend
English: --1 ≥ 50x106 CD54+ cells/250mL
Estonian: --1 ≥ 50x106 CD54+ rakku/250 ml
English: EU/1/13/867/001 PROVENGE --1
Estonian: EU/1/13/867/001
English: dispersion for infusion Intravenous use Bag
Estonian: Infusioonidispersioon Intravenoosne kott
English: Alternative treatment options should be considered.
Estonian: Tuleks kaaluda alternatiivseid ravivõimalusi.
English: When getting up, do so as slowly as possible.
Estonian: Tõuske nii aeglaselt kui võimalik.
English: Talk to your doctor about how to avoid infecting other people.
Estonian: Arutage oma arstiga, kuidas vältida teiste inimeste nakatamist.
English: After first opening: 60 days
Estonian: Pärast esmakordset avamist: 60 päeva
English: Remove the bottle cap (A).
Estonian: Eemaldage pudeli kork (A).
English: CELSENTRI should always be taken by mouth.
Estonian: CELSENTRIt peab alati manustama suu kaudu.
English: CELSENTRI can be taken with or without food.
Estonian: CELSENTRIt võib võtta koos toiduga või ilma.
English: Stop taking CELSENTRI.
Estonian: Lõpetage CELSENTRI võtmine.
English: Always take or give this medicine exactly as your doctor has told you.
Estonian: Võtke või andke seda ravimit alati täpselt nii, nagu arst on teile selgitanud.
English: Difference1 (Confidence Interval2)
Estonian: Erinevus1 (usaldusintervall2)
English: The MOTIVATE studies were extended beyond 96 weeks, with an observational phase extended to 5 years in order to assess the long term safety of maraviroc.
Estonian: MOTIVATE uuringuid pikendati üle 96 nädala, kusjuures vaatlusfaasi pikendati 5 aastani, et hinnata maraviroki pikaajalist ohutust.
English: This is particularly important if you are also taking some other medicines (see ‘Other medicines and CELSENTRI' later in section 2).
Estonian: See on eriti tähtis, kui võtate ka teatud teisi ravimeid (vt ”Muud ravimid ja CELSENTRI” lõigus 2 allpool).
English: A risk to the newborn/infants cannot be excluded.
Estonian: Ei saa välistada riski vastsündinule/imikule.
English: The results should therefore be interpreted with caution.
Estonian: Neid tulemusi tuleb tõlgendada ettevaatusega.
English: This should be taken into consideration when treating infections such as active tuberculosis and invasive fungal infections.
Estonian: Seda tuleb arvestada eriti selliste nakkuste ravimisel, nagu aktiivne tuberkuloos ja invasiivsed seennakkused.
English: Hold the bottle firmly.
Estonian: Hoidke pudelist tugevalt kinni.
English: CELSENTRI, as part of combination therapy, reduces the amount of virus in your body, and keeps it at a low level.
Estonian: CELSENTRI, osana kombinatsioonravist, vähendab viiruse hulka teie organismis ja hoiab selle madalal tasemel.
English: Typically, such reactions have been observed within the first few weeks or months of initiation of CART.
Estonian: Tavaliselt täheldatakse selliseid reaktsioone CART-ravi alustamise esimeste nädalate või kuude jooksul.
English: This polar metabolite has no significant pharmacological activity.
Estonian: Sellel polaarsel metaboliidil ei ole märkimisväärset farmakoloogilist aktiivsust.
English: Contact your doctor or the nearest hospital immediately.
Estonian: Võtke otsekohe ühendust oma arstiga või pöörduge lähimasse haiglasse.
English: The remainder was excreted as metabolites.
Estonian: Ülejäänud ravim eritati metaboliitidena.
English: CELSENTRI has only been taken by limited numbers of people 65 years or older.
Estonian: CELSENTRIt on võtnud ainult piiratud arv 65-aastasteid ja vanemaid inimesi.
English: If you are pregnant, if you become pregnant, or if you are planning to have a baby: Talk to your doctor about the risks and benefits of taking CELSENTRI.
Estonian: Kui te olete rase, rasestute või kavatsete rasestuda: Rääkige oma arstiga CELSENTRI võtmisega seotud riskidest ja kasust.
English: Component of a multipack, cannot be sold seperately.
Estonian: Mitmikpakendi komponent, ei saa müüa eraldi.
English: Recommendations concerning coadministration in adults
Estonian: Soovitused seoses koosmanustamisega täiskasvanutel
English: When they start treatment, the immune system becomes stronger, so the body starts to fight infections.
Estonian: Pärast ravi alustamist muutub immuunsüsteem tugevamaks ja organism hakkab infektsioonide vastu võitlema.
English: Traditional IC50/IC90 fold-change was not a useful parameter to measure phenotypic resistance, as those values were sometimes unchanged despite significantly reduced sensitivity.
Estonian: Traditsiooniline IC50/IC90 suhte muutus ei olnud sobiv parameeter fenotüübilise resistentsuse mõõtmiseks, sest need väärtused olid mõnikord muutumatud hoolimata oluliselt vähenenud tundlikkusest.
English: If you forget to take or give CELSENTRI
Estonian: Kui te unustate CELSENTRIt võtta või anda
English: It is not known how common this condition is.
Estonian: Ei ole teada, kui sageli seda haigusseisundit esineb.
English: Any inflammatory symptoms should be evaluated and treatment initiated when necessary.
Estonian: Ükskõik millist põletikusümptomit tuleb hinnata ja alustada vajadusel ravi.
English: Age (years) (Range, years)
Estonian: Vanus (aastates) (Vanusevahemik, aastates) Meessugu
English: Insert the applicator (C) firmly into the adapter.
Estonian: Pange aplikaator (C) kindlalt adapterisse.
English: The population was 52% female and 69% black, with mean age of 10 years (range: 2 years to 17 years).
Estonian: Uuringus osalejatest 52% olid naissoost ja 69% mustanahalised keskmise vanusega 10 aastat (vahemik: 2 aastat kuni 17 aastat).
English: The volume of distribution of maraviroc is approximately 194 L.
Estonian: Maraviroki jaotusruumala on umbes 194 l.
English: Read the information ‘Other possible side effects of combination therapy for HIV' in Section 4 of this leaflet.
Estonian: Lugege teavet ”HIV kombinatsioonravi muud võimalikud kõrvaltoimed” käesoleva infolehe lõigus 4.
English: Further details for concomitantly administered medicinal products are provided below (see Table
Estonian: Täpsemad detailid samaaegselt manustatavate ravimite kohta on toodud allpool (vt tabel 2).
English: Therefore there is a need to start therapy shortly after a tropism test.
Estonian: Seetõttu tuleb patsientidel ravi alustada kohe pärast tropismi testimist.
English: CCR5 antagonists could potentially impair the immune response to certain infections.
Estonian: CCR5 antagonistid võivad potentsiaalselt nõrgendada immuunvastust mõnedele nakkustele.
English: Combination with two inducers has not been studied.
Estonian: Kahe indutseerija kombinatsiooni ei ole uuritud.
English: Repeat steps 3 to 7 in the same way until the whole dose has been taken.
Estonian: Korrake punkte 3-7, kuni olete manustanud kogu annuse.
English: The position of these mutations was not consistent between different isolates.
Estonian: Nende mutatsioonide paiknemine ei olnud erinevates isolaatides samasugune.
English: Date of first authorisation: 18th September 2007 Date of latest renewal: 20 July 2012
Estonian: Müügiloa viimase uuendamise kuupäev: 20. juuli 2012
English: 30 to less than 40 kg at least 40 kg
Estonian: 30 kuni alla 40 kg vähemalt 40 kg